

Cover Story
FDA will hold a three-day meeting of the Oncologic Drugs Advisory Committee April 27-29 to consider five indications that received accelerated approvals, but that have not been shown to produce a clinical benefit in confirmatory trials.
In Brief
Clinical Roundup


Drugs & Targets


Trending Stories
- Betty Ford and the press conference that changed oncology
- ARPA-H placed outside NIH in authorization bill approved in a 336-85 House vote
- NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups
- Alex A. Adjei named chair of Cleveland Clinic Taussig Cancer Institute
- Dave Boule confronted polycythemia vera with an accountant’s consistency
- Harold Varmus reflects on the life of John Edward Porter, a House appropriator—and his friend
Porter helped orchestrate the doubling of the NIH budget between 1998 and 2003